Beijing Hotgen Biotech Co.,Ltd.’s Net Profit Dropped 25.6% in First Three Quarters of 2022

Beijing Hotgen Biotech Co.,Ltd. (北京热景生物技术股份有限公司) (688068.SH) reported a net profit of 1.1 billion yuan in the first three quarters of 2022, down 25.6% year-on-year.

Meanwhile, the company posted 3 billion yuan in revenue, down 20.7% year-on-year.

At the end of the reporting period, it had 3.9 billion yuan in total assets and 348.1 million yuan in total liabilities, with a liability-to-asset ratio of 8.9%.